{"uri": "eng-9433531", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Interleukin_12", "type": "wiki", "score": 100, "label": {"eng": "Interleukin 12"}}, {"uri": "http://en.wikipedia.org/wiki/Gilead", "type": "loc", "score": 82, "label": {"eng": "Gilead"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Cancer_immunotherapy", "type": "wiki", "score": 73, "label": {"eng": "Cancer immunotherapy"}}, {"uri": "http://en.wikipedia.org/wiki/Gilead_Sciences", "type": "org", "score": 67, "label": {"eng": "Gilead Sciences"}}, {"uri": "http://en.wikipedia.org/wiki/Neoplasm", "type": "wiki", "score": 60, "label": {"eng": "Neoplasm"}}, {"uri": "http://en.wikipedia.org/wiki/Combination_therapy", "type": "wiki", "score": 58, "label": {"eng": "Combination therapy"}}, {"uri": "http://en.wikipedia.org/wiki/Common_stock", "type": "wiki", "score": 56, "label": {"eng": "Common stock"}}, {"uri": "http://en.wikipedia.org/wiki/Molecule", "type": "wiki", "score": 56, "label": {"eng": "Molecule"}}, {"uri": "http://en.wikipedia.org/wiki/Biotechnology", "type": "wiki", "score": 55, "label": {"eng": "Biotechnology"}}, {"uri": "http://en.wikipedia.org/wiki/Drug_development", "type": "wiki", "score": 53, "label": {"eng": "Drug development"}}, {"uri": "http://en.wikipedia.org/wiki/Cancer", "type": "wiki", "score": 53, "label": {"eng": "Cancer"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 47, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/Phases_of_clinical_research", "type": "wiki", "score": 44, "label": {"eng": "Phases of clinical research"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 40, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Private_placement", "type": "wiki", "score": 38, "label": {"eng": "Private placement"}}, {"uri": "http://en.wikipedia.org/wiki/Equity_(finance)", "type": "wiki", "score": 37, "label": {"eng": "Equity (finance)"}}, {"uri": "http://en.wikipedia.org/wiki/Chemotherapy", "type": "wiki", "score": 35, "label": {"eng": "Chemotherapy"}}, {"uri": "http://en.wikipedia.org/wiki/Tumor_microenvironment", "type": "wiki", "score": 34, "label": {"eng": "Tumor microenvironment"}}, {"uri": "http://en.wikipedia.org/wiki/Cytokine", "type": "wiki", "score": 33, "label": {"eng": "Cytokine"}}, {"uri": "http://en.wikipedia.org/wiki/Interleukin_2", "type": "wiki", "score": 32, "label": {"eng": "Interleukin 2"}}, {"uri": "http://en.wikipedia.org/wiki/Security_(finance)", "type": "wiki", "score": 30, "label": {"eng": "Security (finance)"}}, {"uri": "http://en.wikipedia.org/wiki/License", "type": "wiki", "score": 27, "label": {"eng": "License"}}, {"uri": "http://en.wikipedia.org/wiki/Bain_Capital", "type": "org", "score": 26, "label": {"eng": "Bain Capital"}}, {"uri": "http://en.wikipedia.org/wiki/Waltham,_Massachusetts", "type": "loc", "score": 26, "label": {"eng": "Waltham, Massachusetts"}, "location": {"type": "place", "label": {"eng": "Waltham, Massachusetts"}, "country": {"type": "country", "label": {"eng": "United States"}}}}, {"uri": "http://en.wikipedia.org/wiki/GlobeNewswire", "type": "org", "score": 21, "label": {"eng": "GlobeNewswire"}}, {"uri": "http://en.wikipedia.org/wiki/PacWest_Bancorp", "type": "org", "score": 12, "label": {"eng": "PacWest Bancorp"}}, {"uri": "http://en.wikipedia.org/wiki/LinkedIn", "type": "org", "score": 7, "label": {"eng": "LinkedIn"}}, {"uri": "http://en.wikipedia.org/wiki/China", "type": "loc", "score": 5, "label": {"eng": "China"}, "location": {"type": "country", "label": {"eng": "China"}}}], "eventDate": "2024-03-28", "totalArticleCount": 16, "title": {"eng": "Gilead secures license for cancer treatment candidate By Investing.com"}, "summary": {"eng": "FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) and Xilio Therapeutics, Inc. (NASDAQ:XLO) have entered into an exclusive licensing agreement to develop and commercialize Xilio's tumor-activated interleukin-12 (IL-12) program, including its clinical-stage molecule XTX301. The partnership aims to enhance Gilead's portfolio in the immuno-oncology space and utilize Xilio's tumor-activation technology to address a variety of solid tumors.\n\nUnder the agreement, Gilead will make an upfront pay"}, "location": null, "categories": [{"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals", "label": "dmoz/Business/Biotechnology and Pharmaceuticals", "wgt": 30}, {"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Pharmaceuticals", "label": "dmoz/Business/Biotechnology and Pharmaceuticals/Pharmaceuticals", "wgt": 51}, {"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Contract_Research_Organizations", "label": "dmoz/Business/Biotechnology and Pharmaceuticals/Contract Research Organizations", "wgt": 16}, {"uri": "news/Business", "label": "news/Business", "wgt": 92}], "articleCounts": {"eng": 16}, "sentiment": 0.2705882352941176, "wgt": 449280000, "relevance": 2}